• 2026.11.20 (Fri)
  • All articles
  • LOGIN
  • JOIN
Global Economic Times
한인동포뉴스(상단)
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
    • International Student Report
    • With Ambassador
  • Column
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
MENU
 
Home > World

Health Insurer Proposes "Subscription-Plus-Bonus" Model to Curb Skyrocketing Weight-Loss Drug Costs

Greace Nunez Correspondent / Updated : 2026-11-20 06:21:19
  • -
  • +
  • Print
California-based Ascendian is negotiating with Eli Lilly and Novo Nordisk to tie GLP-1 drug payments to actual patient outcomes.

As the surging popularity of GLP-1 weight-loss and diabetes medications drives up healthcare premiums, a major U.S. health insurer is exploring an unconventional payment structure: paying pharmaceutical companies like a gym membership, complete with performance bonuses.

Ascendian, the parent company of Blue Shield of California, is proposing a two-tiered pricing model for blockbuster drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Under the proposed framework, the insurer would pay a flat monthly subscription fee to drugmakers, granting all eligible members access to the medications as needed. Pharmaceutical companies would then receive additional bonus payments only if patients demonstrate measurable clinical improvements, such as significant weight loss or lowered blood sugar levels.

In a recent interview, Ascendian CEO Paul Markovich noted that the company is actively discussing this hybrid subscription-and-outcome model with both Eli Lilly and Novo Nordisk.

Balancing Predictability and Access

The push for an alternative pricing strategy comes as employers and insurers increasingly balk at the high costs of obesity treatments. According to data from consulting firm Willis Towers Watson, the share of employers covering GLP-1 drugs for weight loss dipped from 56% to 53% this year, reflecting growing concerns over long-term financial sustainability.

Ascendian’s proposed model aims to solve this dilemma for both payers and manufacturers:

For Insurers and Patients: A fixed monthly fee makes healthcare spending more predictable, while tying extra payouts to proven results prevents runaway costs. Ascendian expects this structure to significantly lower out-of-pocket expenses for patients and keep coverage accessible.
For Drugmakers: Rather than demanding steep upfront discounts, the model guarantees steady, predictable monthly revenue and sales volume.

Hurdles to Implementation

Despite its theoretical appeal, outcomes-based and subscription pricing models have historically struggled to gain traction—largely remaining confined to ultra-expensive gene therapies. A report last year by the Institute for Clinical and Economic Review (ICER) indicated that while major healthcare buyers have explored subscription models, widespread adoption has been elusive.

Several practical challenges remain:

Measuring Efficacy: Determining whether a patient's weight loss is strictly due to the medication or other lifestyle factors is complex, making standardized performance metrics difficult to establish.
Estimating Demand: Because widespread GLP-1 adoption is still relatively new, accurately forecasting utilization rates to set a fair subscription price is challenging.
Regulatory Barriers: Markovich acknowledged that the fine print is still being negotiated and noted that regulatory adjustments may be required to make such contracts legally viable.

A Broader Push Against High Drug Prices 

This initiative builds upon Markovich’s broader three-year campaign to overhaul prescription drug pricing. Previously, the insurer broke away from relying solely on CVS Health as its pharmacy benefit manager (PBM) to foster competition, aiming for $500 million in annual savings. While the company has saved roughly $150 million a year so far and secured direct pricing deals for fewer than a dozen drugs, Markovich admitted that traditional direct negotiations alone have not yielded a major breakthrough for GLP-1 costs.

Ultimately, the success of this novel payment experiment will hinge on how the insurer and drugmakers define clinical success, share patient data, handle treatment dropouts, and calculate out-of-pocket costs.

[Copyright (c) Global Economic Times. All Rights Reserved.]

  • #Cherry Garden
  • #HalalFood
  • #Halal
  • #Petlife
  • #Halalhorizone
  • #Hormuz Impasse
  • #Joseon
  • #globaleconomictimes
  • #micore
Greace Nunez Correspondent
Greace Nunez Correspondent

Popular articles

  • Amazon Courts ‘Global No. 1’ K-Beauty

  • Bill Gates: "AI Will Replace Most Human Jobs... Extreme Turmoil Expected Over the Next 20 Years"

  • "Sinokoo Marine accounts for 37% of crude oil transiting the Strait of Hormuz in September"

I like it
Share
  • Facebook
  • X
  • Kakaotalk
  • LINE
  • BAND
  • NAVER
  • https://globaleconomictimes.kr/article/1065561549180107 Copy URL copied.
Comments >

Comments 0

Weekly Hot Issue

  • Putin Shakes Hands with a Smiling Trump... Behind Him Was the 'Black Nuclear Briefcase'
  • Nvidia Offers Early Pay Reviews to Calm Staff After Jensen Huang’s Exit
  • Massive Women’s Safety Network ‘Are We Dating the Same Guy?’ Halts New Posts Amid Legal and Platform Pressures
  • Historic US-China-Russia Summit Yields Grand Rhetoric, Few Concrete Results
  • Commuters Face Potential Delays as Seoul Subway Workers Launch Work-to-Rule Action
  • Lee Urges Reopening of North Korea Dialogue at APEC After Rare Encounter with Putin

Most Viewed

1
South Korea and Ethiopia Sign Trilateral MOU to Introduce Liquid-Based Cytology (LBC) Technology for Cervical Cancer Diagnosis
2
Meeting Christmas Early!… Busan Dessert Sales Event "Daldal The Market" Held
3
World Citizens are Flying Directly to Busan... The Era of 4 Million Foreigners is Just Around the Corner
4
Eating 100g of Baechu Kimchi Daily Linked to Lower High-Cholesterol Risks
5
First Snow and Freeze Hit Korea as Winter Officially Begins on 'Ipdeong'
체리가든 스토리
nutri huevos
로타리
동포저널

Hot Issue

Historic US-China-Russia Summit Yields Grand Rhetoric, Few Concrete Results

KOSPI Clings to 5,000-Point Mark Amid Heavy Foreign Selling; Year-End Rally Seen as Unlikely

Commuters Face Potential Delays as Seoul Subway Workers Launch Work-to-Rule Action

Fashion Runway Show 2026

Let’s recycle the old blankets in Jeju Island’s closet instead of incinerating them.

Global Economic Times
korocamia@naver.com
CEO : LEE YEON-SIL
Publisher & Editor : KO YONG-CHUL
Registration number : Seoul, A55681
Registration Date : 2024-10-24
Youth Protection Manager: KO YONG-CHUL
Singapore Headquarters
5A Woodlands Road #11-34 The Tennery. S'677728
Korean Branch
Phone : +82(0)10 4724 5264
#304, 6 Nonhyeon-ro 111-gil, Gangnam-gu, Seoul
Copyright © Global Economic Times All Rights Reserved
  • News K
  • 반달곰 프로젝트
  • 광고문의
Search
Category
  • All articles
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being 
    • 전체
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life 
    • 전체
    • International Student Report
    • With Ambassador
  • Column 
    • 전체
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
  • Overseas Koreans
  • Multicultural News